Examining international practices in the management of pregnant women with von Willebrand disease

• Published in: Journal of thrombosis and haemostasis Vol. 20; no. 1; pp. 82 - 91
• Main Authors: Lavin, Michelle, Sánchez Luceros, Analia, Kouides, Peter, Abdul‐Kadir, Rezan, O’Donnell, James S., Baker, Ross I., Othman, Maha, Haberichter, Sandra L.
• Format: Journal Article
• Language: English
• Published: England Elsevier Limited 01.01.2022
• Subjects: Anesthesia; Decision making; Disease management; Female; Ferritin; Hemorrhage; Humans; Plasma; Postpartum; Postpartum Hemorrhage - diagnosis; Postpartum Hemorrhage - prevention & control; Postpartum Period; Pregnancy; Pregnant Women; Prophylaxis; Supplements; Thrombosis; von Willebrand disease; von Willebrand Diseases - diagnosis; von Willebrand Diseases - therapy; Von Willebrand factor; von Willebrand Factor - analysis; Womens health; von Willebrand disease; postpartum; von Willebrand factor; pregnancy; anesthesia
• ISSN: 1538-7933; 1538-7836; 1538-7836
• DOI: 10.1111/jth.15561

Background The management of pregnant women with von Willebrand disease (VWD) is complex as physiological pregnancy‐induced increases in plasma von Willebrand factor (VWF) may be blunted or absent. Women with VWD experience a heightened risk of postpartum hemorrhage (PPH) and special consideration must be given regarding neuraxial anesthesia (NA) and the need for prophylaxis at time of delivery. These challenges are compounded by a lack of robust evidence to guide clinical decision‐making. Objectives and Methods To determine the current international clinical practices in the management of pregnancy for women with VWD, the International Society on Thrombosis and Haemostasis (ISTH) conducted an international survey of health‐care providers (HCP). Results One hundred thirty‐two respondents from 39 countries were included in the final analysis. Variations in clinical practice were identified in antenatal (monitoring of plasma VWF and ferritin levels), peripartum (optimal plasma VWF target at delivery) and postpartum management (definitions used for PPH and postpartum monitoring). A key area of divergence was suitability for NA for women with type 2 and type 3 VWD, with many respondents advising against the use of NA even with VWF supplementation (29% type 2 VWD, 37% type 3 VWD) but others advising use once plasma VWF activity was >50 IU/dL (57% type 2 VWD; 50% type 3 VWD). Conclusions This survey highlighted areas of uncertainty surrounding common management issues for pregnant women with VWD. These data underscore the need for international collaborative research efforts focused on peripartum management to improve care for pregnant women with VWD.